Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Institut Pasteur

Universitè De Montpellier

Bio-rad Europe Gmbh

Bio-rad Pasteur

Chu Monpellier

Bio-rad Innovations

Chu Montpellier

Claude Granier

Bernard Pau

Luc Montagnier

Solange Chamaret

Martine Cerutti

Francois Yves Rieunier

Thierry Chardes

Franck Molina

Stephane Ferris

Fabienne Babin

Sylvie Marie-France Trinquier

Catherine Christiane Marie Larue

Nicolas Salvetat

Christian Devaux

Randa Siala

Laurence Briant-Longuet

Gérard Devauchelle

Charles Didier Calzolari

Odile Suzanne Helene Flecheux

Eric Renard

Herve Rochat

El M Bahraoui

Jurphaar V Rietschoten

Jean-Marc Sabatier

Sylvie Villard

Laurence Molina

Cédric Bes

The present invention concerns a method for the in vitro detection of an increased risk of diabetic nephropathy in a subject suffering from diabetes and being normoalbuminuric. Another aspect of the invention pertains to a method for the in vitro identification of a marker for prediction of diabetic nephropathy. Finally, the invention concerns a kit comprising means for detecting at least two proteins selected from the group consisting of heparan sulfate proteoglycan core protein or fragments thereof, carbonic anhydrase 1, prothrombin or fragments thereof, tetranectin, CD59 glycoprotein, plasma serine protease inhibitor, mannan-binding lectin serine protease 2 or isoforms thereof, antithrombin-III, alpha-1-antitrypsin, collagen alpha-1(I) chain, alpha-enolase, histone H2B type 1-O, glutaminyl-peptide cyclotransferase, protein AMBP and zinc-alpha-2-glycoprotein.

Early prediction markers of diabetic nephropathy

Peptide or pseudopeptide decoys binding to antibodies capable of being developed against endogenous proteins within the framework of autoimmune pathologies or against exogenous proteins administered to patients, in particular within the framework of pathologies due to a deficiency in these proteins, the amino acid sequence of the peptide or pseudopeptide decoys differing from that of the epitopes recognized by the antibodies, for the preparation of medicaments intended for the prevention or treatment of the autoimmune pathologies, or for the prevention or treatment of the disorders linked to the appearance of antibodies directed against the exogenous proteins.

Peptide decoys for the preparation of medicaments intended for the prevention or treatment of autoimmune pathologies or disorders linked to the appearance of antibodies directed against exogenous proteins

A mutant Fab fragment of the 13B8.2 anti-CD4 antibody that binds a CD4 molecule and includes a mutation of at least one residue in a position situated in the VH variable domain of the heavy chain and/or in a position situated in the V&#x3ba; variable domain of the light chain.

Mutant Fab fragments of the chimeric 13B8.2 anti-CD4 antibody and their applications

The invention relates to synthetic biepitope compounds which can be used as standards in immunoassays, for the assay of troponin I, method for preparing them, compositions and kits containing such compounds as well as the immunoassay methods using such compounds.

Synthetic bioepitope compounds which can be used as standards in the biological assays of Troponin I

Polypeptides encoded by the nef gene of Human Immunodeficiency Virus (HIV), which is the major etiological agent of Acquired Immune Deficiency Syndrome (AIDS), are identified. The polypeptides, a diagnostic method for detecting antibodies to HIV in biological fluids, a diagnostic kit for carrying out the method, and pharmaceutical compositions containing the polypeptides are described. The polypeptides are useful in viral vaccines and for the early detection of HIV infection in humans.

Diagnostic method and composition for early detection of HIV infection

Growing community of inventors

Clapiers, France

Claude Granier